MetaVia (MTVA) Stock Price

MetaVia Price

NASDAQ·CLOSED
1.32
​
Market closed

MetaVia stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia business model & stock analysis

NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market.

Frequently asked questions about MetaVia

8 analysts currently rate the MetaVia stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the MetaVia share trades at 1.18 EUR (1.32 USD).

The MetaVia share (MTVA) is listed on 1 stock exchanges, including: NASDAQ (NRBO).

The revenue cannot currently be calculated for MetaVia.

The expected profit of MetaVia is -8.08 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of MetaVia is currently -0.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MetaVia stock.

The P/S cannot be calculated for MetaVia currently.

The Eulerpool Quality Score for MetaVia is 2/10.

The ISIN of MetaVia is US64132R5037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MetaVia is A2PXT4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MetaVia is MTVA. The ticker symbol is used to trade MetaVia shares on the stock exchange.

Fair ValueTerminal
1.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 5, 2016
ISIN
US64132R5037
Cusip
64132R107
Sedol
BKPFFV5
Market capitalization
4.24 M USDMicro Cap
52-Week Range
PEG
0.02
P/E ratio
P/Ee 2026
-0.38
P/Ee 2027
-0.40
P/Ee 2028
-0.60
P/Ee 2029
-0.69
P/Ee 2030
-0.75
P/S
P/Se
—
EV/EBIT
0.43
P/B Ratio
0.80
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-234.04 %
Last updated Oct 22, 2026, 10:30 PM

MetaVia Peer Group

MetaVia Ticker

NASDAQ · NRBO

All fundamentals and in-depth analysis of MetaVia

Our stock analysis for MetaVia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MetaVia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.